David A. Baidal
YOU?
Author Swipe
View article: SUN-555 A Case Of Autoimmunity Induced Pancreatic Graft Dysfunction.
SUN-555 A Case Of Autoimmunity Induced Pancreatic Graft Dysfunction. Open
Disclosure: A. Olayiwola: None. F. Vendrame: None. D. Baidal: None. G. Burke: None. A. Pugliese: None. R. Varghese: None. Introduction: Pancreas transplantation is a well-established treatment for patients with Type 1 Diabetes Mellitus (T1…
View article: 25(OH) Vitamin D Levels and Severity of Type 1 Diabetes in Youth and Adults With Recent-Onset Disease
25(OH) Vitamin D Levels and Severity of Type 1 Diabetes in Youth and Adults With Recent-Onset Disease Open
Objective To test 25-hydroxy vitamin D (25(OH)D) levels among subjects with new-onset type 1 diabetes (T1D) and their association with fasting and stimulated C-peptide at study entry in an open-label randomized trial. Methods We conducted …
View article: <b>Islet Transplantation vs. Standard of Care for Type 1 Diabetes Complicated by Severe Hypoglycemia from the Collaborative Islet Transplant Registry (CITR) and the T1D Exchange (T1DX) Registry</b>
<b>Islet Transplantation vs. Standard of Care for Type 1 Diabetes Complicated by Severe Hypoglycemia from the Collaborative Islet Transplant Registry (CITR) and the T1D Exchange (T1DX) Registry</b> Open
Objective Islet transplantation is recently FDA-approved for adults with type 1 diabetes complicated by recurrent severe hypoglycemia events (SHE). We sought to understand the long-term benefit for glycemic control and risk of immunosuppre…
View article: <b>Islet Transplantation vs. Standard of Care for Type 1 Diabetes Complicated by Severe Hypoglycemia from the Collaborative Islet Transplant Registry (CITR) and the T1D Exchange (T1DX) Registry</b>
<b>Islet Transplantation vs. Standard of Care for Type 1 Diabetes Complicated by Severe Hypoglycemia from the Collaborative Islet Transplant Registry (CITR) and the T1D Exchange (T1DX) Registry</b> Open
Objective Islet transplantation is recently FDA-approved for adults with type 1 diabetes complicated by recurrent severe hypoglycemia events (SHE). We sought to understand the long-term benefit for glycemic control and risk of immunosuppre…
View article: Islet Transplantation Versus Standard of Care for Type 1 Diabetes Complicated by Severe Hypoglycemia From the Collaborative Islet Transplant Registry and the T1D Exchange Registry
Islet Transplantation Versus Standard of Care for Type 1 Diabetes Complicated by Severe Hypoglycemia From the Collaborative Islet Transplant Registry and the T1D Exchange Registry Open
OBJECTIVE Islet transplantation was recently US Food and Drug Administration approved for adults with type 1 diabetes complicated by recurrent severe hypoglycemia events (SHEs). We sought to understand the long-term benefit for glycemic co…
View article: Islets Transplantation at a Crossroads - Need for Urgent Regulatory Update in the United States: Perspective Presented During the Scientific Sessions 2021 at the American Diabetes Association Congress
Islets Transplantation at a Crossroads - Need for Urgent Regulatory Update in the United States: Perspective Presented During the Scientific Sessions 2021 at the American Diabetes Association Congress Open
Clinical islet allotransplantation has been successfully regulated as tissue/organ for transplantation in number of countries and is recognized as a safe and efficacious therapy for selected patients with type 1 diabetes mellitus. However,…
View article: Editorial: Diabetes, transplantation and regenerative medicine
Editorial: Diabetes, transplantation and regenerative medicine Open
Keywords: diabetes mellitus, transplantation, post-transplant diabetes mellitus (PTDM), beta-cell replacement therapy, pancreas transplantation, islet transplantation, stem cell-based therapy, type 1 diabetes
View article: Impact of GAD65 and IA2 autoantibodies on islet allograft survival
Impact of GAD65 and IA2 autoantibodies on islet allograft survival Open
Introduction Islet transplantation (ITx) shows promise in treating T1D, but the role of islet autoantibodies on graft survival has not been clearly elucidated. We aimed to analyze the effect of GAD65 and IA2 autoantibody status on graft su…
View article: Comparison of Glycemic Control Between In-Person and Virtual Diabetes Consults in Hospitalized Patients With Diabetes
Comparison of Glycemic Control Between In-Person and Virtual Diabetes Consults in Hospitalized Patients With Diabetes Open
Background: There is limited evidence that the diabetes in-person consult in hospitalized patients can be replaced by a virtual consult. During COVID-19 pandemic, the diabetes in-person consult service at the University of Miami and Miami …
View article: Hydroxychloroquine in Stage 1 Type 1 Diabetes
Hydroxychloroquine in Stage 1 Type 1 Diabetes Open
OBJECTIVE Innate immune responses may be involved in the earliest phases of type 1 diabetes (T1D). RESEARCH DESIGN AND METHODS To test whether blocking innate immaune cells modulated progression of the disease, we randomly assigned 273 ind…
View article: Matching for HLA-DR excluding diabetogenic HLA-DR3 and HLA-DR4 predicts insulin independence after pancreatic islet transplantation
Matching for HLA-DR excluding diabetogenic HLA-DR3 and HLA-DR4 predicts insulin independence after pancreatic islet transplantation Open
Introduction In pancreatic islet transplantation, the exact contribution of human leukocyte antigen (HLA) matching to graft survival remains unclear. Islets may be exposed to allogenic rejection but also the recurrence of type 1 diabetes (…
View article: Predictive Value of C-peptide Measures for Clinical Outcomes of Beta Cell Replacement Therapy in Type 1 Diabetes: Report from the Collaborative Islet Transplant Registry (CITR)
Predictive Value of C-peptide Measures for Clinical Outcomes of Beta Cell Replacement Therapy in Type 1 Diabetes: Report from the Collaborative Islet Transplant Registry (CITR) Open
OBJECTIVE To determine C-peptide measures and levels associated with positive glycemic control outcomes following islet transplantation (ITx) in type 1 diabetes. RESEARCH DESIGN AND METHODS We evaluated Collaborative Islet Transplant R…
View article: Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR)
Predictive Value of C-Peptide Measures for Clinical Outcomes of β-Cell Replacement Therapy in Type 1 Diabetes: Report From the Collaborative Islet Transplant Registry (CITR) Open
OBJECTIVE To determine C-peptide measures and levels associated with positive glycemic control outcomes following islet transplant (ITx) in type 1 diabetes. RESEARCH DESIGN AND METHODS We evaluated Collaborative Islet Transplant Registry (…
View article: Predictive Value of C-peptide Measures for Clinical Outcomes of Beta Cell Replacement Therapy in Type 1 Diabetes: Report from the Collaborative Islet Transplant Registry (CITR)
Predictive Value of C-peptide Measures for Clinical Outcomes of Beta Cell Replacement Therapy in Type 1 Diabetes: Report from the Collaborative Islet Transplant Registry (CITR) Open
OBJECTIVE To determine C-peptide measures and levels associated with positive glycemic control outcomes following islet transplantation (ITx) in type 1 diabetes. RESEARCH DESIGN AND METHODS We evaluated Collaborative Islet Transplant R…
View article: HLA-B Matching Prolongs Allograft Survival in Islet Cell Transplantation
HLA-B Matching Prolongs Allograft Survival in Islet Cell Transplantation Open
Islet cell transplantation (ITx) is an effective therapeutic approach for selected patients with type 1 diabetes with hypoglycemia unawareness and severe hypoglycemia events. In organ transplantation, human leukocyte antigen (HLA) mismatch…
View article: Increase Access, Reduce Disparities: Recommendations for Modifying Medicaid CGM Coverage Eligibility Criteria
Increase Access, Reduce Disparities: Recommendations for Modifying Medicaid CGM Coverage Eligibility Criteria Open
Numerous studies have demonstrated the clinical value of continuous glucose monitoring (CGM) in type 1 diabetes (T1D) and type 2 diabetes (T2D) populations. However, the eligibility criteria for CGM coverage required by the Centers for Med…
View article: Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes
Oral Glucose Tolerance Test Measures of First-phase Insulin Response and Their Predictive Ability for Type 1 Diabetes Open
Context Decreased first-phase insulin response (FPIR) during intravenous glucose tolerance testing (IVGTT) is an early indicator of β-cell dysfunction and predictor of type 1 diabetes (T1D). Objective Assess whether oral glucose tolerance …
View article: IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes
IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes Open
Type 1 diabetes mellitus (T1DM) is an autoimmune disease. Based on previous research, study doctors think that giving medicines to affect the immune system soon after diabetes is diagnosed may stop, delay or decrease the destruction of bet…
View article: Prolonged Islet Allograft Function is Associated With Female Sex in Patients After Islet Transplantation
Prolonged Islet Allograft Function is Associated With Female Sex in Patients After Islet Transplantation Open
Background Islet transplantation (ITx) has proved to be effective in preventing severe hypoglycemia and improving metabolic control in selected subjects with type 1 diabetes. Long-term graft function remains a challenge. Estrogens have bee…
View article: Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts
Time to Peak Glucose and Peak C-Peptide During the Progression to Type 1 Diabetes in the Diabetes Prevention Trial and TrialNet Cohorts Open
OBJECTIVE To assess the progression of type 1 diabetes using time to peak glucose or C-peptide during oral glucose tolerance tests (OGTTs) in autoantibody-positive relatives of people with type 1 diabetes. RESEARCH DESIGN AND METHODS We ex…
View article: Dual‐hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions
Dual‐hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions Open
Over the last few years, technological advances have led to tremendous improvement in the management of type 1 diabetes (T1D). Artificial pancreas systems have been shown to improve glucose control compared with conventional insulin pump t…
View article: Survival After Islet Transplantation in Subjects With Type 1 Diabetes: Twenty-Year Follow-Up
Survival After Islet Transplantation in Subjects With Type 1 Diabetes: Twenty-Year Follow-Up Open
Type 1 diabetes (T1D) is associated with premature mortality due to acute and chronic diabetes-related complications (1). Severe hypoglycemic events (SHEs) and impaired awareness of hypoglycemia are significant contributors to the increase…
View article: Long-term Persistence of Allosensitization After Islet Allograft Failure
Long-term Persistence of Allosensitization After Islet Allograft Failure Open
Background. Allosensitization has been reported after discontinuation of immunosuppression following graft failure in islet transplantation (ITx) recipients, though duration of its persistence is unknown. Methods. We evaluated 35 patients …
View article: Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial
Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial Open
Acute respiratory distress syndrome (ARDS) in COVID-19 is associated with high mortality. Mesenchymal stem cells are known to exert immunomodulatory and anti-inflammatory effects and could yield beneficial effects in COVID-19 ARDS. The obj…
View article: Islet cell transplantation: the effects of COVID-19 pandemic
Islet cell transplantation: the effects of COVID-19 pandemic Open
BACKGROUND: Coronavirus Disease 2019 (COVID-19) caused by SARS-CoV-2 coronavirus is a worldwide epidemic. Estimates of the infection vary by country and region, and US reports over a quarter of the total COVID-19 cases, reported worldwide.…
View article: Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
Exenatide extended release in patients with type 1 diabetes with and without residual insulin production Open
Aims To test whether a long‐acting GLP‐1 receptor agonist would improve glucose control in patients with type 1 diabetes (T1D) and to determine whether the presence of residual beta cell function would affect the response. In addition, we …
View article: The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis
The Effect of Ethnicity in the Rate of Beta-Cell Functional Loss in the First 3 Years After Type 1 Diabetes Diagnosis Open
Objective We set forth to compare ethnicities for metabolic and immunological characteristics at the clinical diagnosis of type 1 diabetes (T1D) and assess the effect of ethnicity on beta-cell functional loss within 3 years after clinical …
View article: Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS).
Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS). Open
The coronavirus SARS-CoV-2 is cause of a global pandemic of a pneumonia-like disease termed Coronavirus Disease 2019 (COVID-19). COVID-19 presents a high mortality rate, estimated at 3.4%. More than 1 out of 4 hospitalized COVID-19 patient…